NYSE · LLY

Eli Lilly & Co.

$1,196.03 +$10.16 (+0.86%) 1D After hours
Session Pulse Overnight session 1 mentions on Fri · 1 bullish / 0 bearish tags No new SEC filings since Mon close its sector ranked 6/11 this week Full pulse →
Charting by TradingView

Key Metrics

$1.06T
Market cap
41.84×
P/E · TTM
$72.25B
Revenue · TTM
$25.28B
Net income
EPS · TTM $28.07
Dividend yield 0.5%
Free cash flow —
Beta · 1Y 0.43
EBITDA · TTM $33.17B
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 30
    The stock moved +9.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 30
  • Feb 4
    The stock moved +10.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 4

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.06T
Enterprise value$1.09T
Shares outstanding891.7M
52-wk range$623.78 – $1,249.45
Avg volume · 20D3.3M
Net cash −$34.97B
Book value / share$34.64
IndustryPharmaceutical Preparations
ExchangeNYSE
About Eli Lilly & Co.
IPO dateJul 9, 1970
Employees50000

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E41.84
P/S14.64
P/FCF—
EV/EBITDA32.94
EV/Sales15.12
Graham №$147.91

Profitability

Gross —
Operating 43.1%
Net 35.0%
FCF —
ROE / ROIC 111.4% · 36.5%

Financial Health

Current ratio1.50
Quick ratio1.10
Debt / equity1.39
Debt / EBITDA 1.31
Net cash −$34.97B
Working capital$18.20B

Cash Flow · TTM

Operating CF $20.48B
Capex —
Free cash flow —
Buybacks $5.26B
Dividends paid $5.59B
Shareholder yield 1.0%

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

$147.91 vs $1,196.03
Trades 8.1× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings